Navigation Links
Novel therapeutic approaches to cure chronic HBV infection
Date:4/24/2013

Exciting new data presented today at the International Liver Congress 2013 include results from early in vitro and in vivo studies targeting covalently closed circular DNA (cccDNA), which may form the basis of a cure for chronic hepatitis B virus (HBV) infection.

HBV cccDNA is organized into mini-chromosomes within the nucleus of infected cells by histone and non-histone proteins. Despite the availability of efficient therapies against HBV, long-term persistence of cccDNA necessitates life-long treatments to suppress the virus. The following three experimental studies demonstrate effective HBV-cccDNA targeting/depletion using novel therapeutic approaches which offer the potential of a cure.

Liver regeneration induces strong reduction of viral replication and cccDNA levels, but not complete cccDNA eradication; without antiviral treatment, de novo HBV infection can be re-established.

Key findings of research in HBV-infected human hepatocytes using the uPA/SCID chimeric mouse system show that liver regeneration induces strong reduction of viral replication and cccDNA levels, with rapid formation of cccDNA-free hepatocytes. However, because complete cccDNA eradication is not achieved, in the absence of antiviral treatment, de novo HBV infection could be re-established in quiescent (non-dividing) human hepatocytes. This suggests that induction of hepatocyte turn-over together with antiviral drugs inducing viral suppression, such as nucleoside analogues and IFN, or blocking cell entry, may accelerate the clearance of the viral minichromosome.

Targeting epigenetic control of nuclear cccDNA minichromosome to suppress HBV transcription and replication may form basis for other therapeutic approaches to curing chronic HBV infection.

In the infected liver cell the rate of replication of HBV is regulated by the acetylation or methylation of histone proteins which surround the cccDNA minichromosome so called epigenetic regulation. In a separate innovative study, the suppression of HBV transcription and replication by small molecules that target the epigenetic control of nuclear cccDNA minichromosome was investigated. The different classes of small molecules studied included: Class I, II and III histone deacetylase inhibitors (HDACi); p300 and PCAF histone acetyltransferases (HAT) inhibitors; hSirt1 activators; JMJD3 histone demethylase inhibitors.

The combined inhibition of p300 and PCAF HATs resulted in an evident reduction of HBV replication which mirrored the decrease of pgRNA transcription. The hSirt1/2 activator MC2791 and the JMJD3 inhibitor MC3119, albeit with different efficiency, inhibited both HBV replication and cccDNA transcription. Results represent a proof of concept that activation of hSirt1 and Ezh2 (through the inhibition of its functional antagonist JMJD3) by small molecules can induce an active epigenetic suppression of HBV cccDNA minichromosome similar to that observed with IFNα, and lead to persistent cccDNA silencing.

Lymphtoxin beta receptor (LTbR) agonisation represents basis for novel alternative therapeutic approach to curing chronic HBV infection.

The final study demonstrated that stimulating the lymphtoxin beta receptor (LTbR) provides an effective, long lasting and non-cytopathic mechanism for achieving effective HBV-cccDNA depletion in infected hepatocytes. Cell culture models including HBV-infected HepaRG cells and primary human hepatocytes were used to test the effect of antibodies stimulating human LTbR (BS1 or CBE11). Results show that a strong and dose-dependent anti-HBV effect was achieved by activation of the LTbR. All HBV replication markers were decreased with this treatment, including cccDNA in cells where HBV infection was already established.

Hepatitis B is the most prevalent cause of chronic viral hepatitis and a major global health problem. Prof. Fabien Zoulim, EASL Educational Councillor commented on the exciting new data: "In chronic hepatitis B infection, the viral genome forms a stable minichromosome - the covalently closed circular DNA (cccDNA) - which can persist throughout the lifespan of the hepatocyte."

"Current treatments focus on suppression of HBV and discovery of compounds directly targeting cccDNA has been one of the major challenges to curing HBV infection; but these preliminary data show novel therapeutic approaches can be applied to successfully target cccDNA with the long-term aspiration of finding a cure" added Prof. Fabien Zoulim.

Disclaimer: the data referenced in this release is based on the submitted abstract. More recent data may be presented at the International Liver Congress 2013.


'/>"/>

Contact: Dimple Natali
easlpressoffice@cohnwolfe.com
44-079-001-38904
European Association for the Study of the Liver
Source:Eurekalert

Related biology news :

1. Development of novel therapies for endothelial damage may heal atherosclerotic plaques
2. Middle-schoolers discover novel chemical bond
3. A novel surface marker helps scientists fish out mammary gland stem cells
4. BUSM researchers identify novel approach to study COPD and treatment efficacy
5. Predicting the next eye pathogen; analysis of a novel adenovirus
6. Researchers find novel mechanism regulating replication of insulin-producing beta cells
7. Researchers find novel way plants pass traits to next generation
8. APL novel method accurately predicts disease outbreaks
9. Novel insights into the evolution of protein networks
10. UMass Amherst researchers reveal mechanism of novel biological electron transfer
11. Novel treatment approach for bladder pain using a herpes simplex virus vector reported
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/20/2017)... , March 20, 2017 PMD Healthcare ... personal spirometer and Wellness Management System (WMS), a remote, ... Founded in 2010, PMD Healthcare is a Medical Device, ... a mission dedicated to creating innovative solutions that empower ... With that intent focus, PMD developed the first ever ...
(Date:3/9/2017)... and MOUNTAIN VIEW, Calif. , March ... Made Simple," and 23andMe , the leading personal ... food choices.  Zipongo can now provide customers with personalized ... health goals and biometrics, but also genetic markers impacting ... Zipongo,s personalized food decision support platform uses ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... ... ... NetDimensions appoints Bill Mastin, a learning technology veteran, as its new Senior Vice ... technologies industry, Mastin joins NetDimensions from the New York office of learning and engagement ... served as SVP of the North America offices and prior to that, he held ...
(Date:4/20/2017)... ... April 20, 2017 , ... Energetiq Technology ... announced today that Chief Executive Officer (CEO) Debbie Gustafson has been appointed to ... global industry association connecting the electronics manufacturing supply chain. The mission of the ...
(Date:4/20/2017)... Minneapolis, MN and Bethesda, MD (PRWEB) , ... ... ... for Advancing Innovation announce the formation of a unique intellectual property (IP) sharing ... commercialization potential of their most promising inventions. A main component of this effort ...
(Date:4/20/2017)... PETACH TIKVAH, Israel , April 20, 2017 ... of adult stem cell technologies for neurodegenerative diseases, announced today ... at the Alliance for Regenerative Medicine,s (ARM) 5 th ... 27, 2017 at 09:40 EDT in Boston ... MD, MHSc, Chief Medical Officer & Chief Operating Officer, will ...
Breaking Biology Technology: